Using JAK2‐V617F‐dependent MPN cell lines as well as primary cells from JAK2‐V617F positive MPN patients, Griner et al. found that cholesterol is required for JAK2‐V617F‐mediated signaling and that JAK2‐V617F‐mediated transformation is sensitive to statins, suggesting that statins could potentially be incorporated into a therapeutic strategy for MPN patients.41 This evidence concerns the gene JAK2 and myeloproliferative neoplasm.